Cargando…

Preclinical evaluation of VAX-IP, a novel bacterial minicell-based biopharmaceutical for nonmuscle invasive bladder cancer

The development of new therapies that can prevent recurrence and progression of nonmuscle invasive bladder cancer remains an unmet clinical need. The continued cost of monitoring and treatment of recurrent disease, along with its high prevalence and incidence rate, is a strain on healthcare economic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsuji, Shingo, Chen, Xuguang, Hancock, Bryan, Hernandez, Veronica, Visentin, Barbara, Reil, Katherine, Sabbadini, Roger, Giacalone, Matthew, Godbey, WT
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824562/ https://www.ncbi.nlm.nih.gov/pubmed/27119118 http://dx.doi.org/10.1038/mto.2016.4

Ejemplares similares

Intravesical VAX014 Synergizes with PD-L1 Blockade to Enhance Local and Systemic Control of Bladder Cancer
por: Tsuji, Shingo, et al.
Publicado: (2022)

Immune responses elicited by bacterial minicells capable of simultaneous DNA and protein antigen delivery
por: Giacalone, Matthew J., et al.
Publicado: (2006)

Intralesional administration of VAX014 facilitates in situ immunization and potentiates immune checkpoint blockade in immunologically cold tumors
por: Reil, Katherine A, et al.
Publicado: (2023)

VAX014, an Oncolytic Therapy, Reduces Adenomas and Modifies Colon Microenvironment in Mouse Model of CRC
por: Grenier, Shea F., et al.
Publicado: (2023)

Production and Characterization of Motile and Chemotactic Bacterial Minicells
por: Ni, Bin, et al.
Publicado: (2021)

Advances in nonmuscle invasive bladder cancer
por: Konety, Badrinath R.
Publicado: (2015)

Minicells as a Damage Disposal Mechanism in Escherichia coli
por: Rang, Camilla U., et al.
Publicado: (2018)

Deterministic Lateral Displacement Microfluidic Chip for Minicell Purification
por: Sherbaz, Ahmad, et al.
Publicado: (2022)

Diagnostics techniques in nonmuscle invasive bladder cancer
por: Soubra, Ayman, et al.
Publicado: (2015)

Intravesical immunotherapy in nonmuscle invasive bladder cancer
por: Jokisch, Jan-Friedrich, et al.
Publicado: (2015)

Active surveillance for nonmuscle invasive bladder cancer
por: Miyake, Makito, et al.
Publicado: (2016)

Minicell‐based fungal RNAi delivery for sustainable crop protection
por: Islam, Md Tabibul, et al.
Publicado: (2021)

Nonmuscle invasive bladder cancer: a primer on immunotherapy
por: Maruf, Mahir, et al.
Publicado: (2016)

New therapies in nonmuscle invasive bladder cancer treatment
por: Rayn, Kareem N., et al.
Publicado: (2018)

Regeneration of Escherichia coli from Minicells through Lateral Gene Transfer
por: Kobayashi, Hideki
Publicado: (2018)

Metabolomics analysis reveals distinct profiles of nonmuscle‐invasive and muscle‐invasive bladder cancer
por: Sahu, Divya, et al.
Publicado: (2017)

Emerging intravesical therapies for management of nonmuscle invasive bladder cancer
por: Tomaszewski, Jeffrey J, et al.
Publicado: (2010)

Liposomes for Use in Gene Delivery
por: Balazs, Daniel A., et al.
Publicado: (2011)

The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer
por: Correa, Andres F., et al.
Publicado: (2015)

Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer
por: van der Meijden, A.P.M.
Publicado: (2006)

Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer
por: Lilge, Lothar, et al.
Publicado: (2020)

HealVax
por: Foerster, John, et al.
Publicado: (2018)

The MinCDJ System in Bacillus subtilis Prevents Minicell Formation by Promoting Divisome Disassembly
por: van Baarle, Suey, et al.
Publicado: (2010)

Engineering the type III secretion system in non-replicating bacterial minicells for antigen delivery
por: Carleton, Heather A., et al.
Publicado: (2013)

Complete structure of the chemosensory array core signalling unit in an E. coli minicell strain
por: Burt, Alister, et al.
Publicado: (2020)

Bacterial minicells to the rescue: cyto‐Immunotherapy for the treatment of late stage cancers with minimal to no toxicity
por: Brahmbhatt, Himanshu, et al.
Publicado: (2021)

To vax or not to vax: Predictors of anti-vax attitudes and COVID-19 vaccine hesitancy prior to widespread vaccine availability
por: Roberts, Hannah A., et al.
Publicado: (2022)

Actin in nonmuscle cells
por: Bonetta, Laura
Publicado: (2005)

Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer (Erratum)
por: Lilge, Lothar, et al.
Publicado: (2020)

The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer
por: Cahill, Ellen M., et al.
Publicado: (2022)

The indispensable role of urinalysis for patients undergoing treatment for nonmuscle invasive bladder cancer
por: Di Gianfrancesco, Luca, et al.
Publicado: (2022)

VAX Software Overview
por: DELPHI Collaboration
Publicado: (1982)

Central VAX upgrade
Publicado: (1987)

VAX support installation
por: Luque, Maria
Publicado: (2021)

Preclinical evaluation of performance, safety and usability of VAX-ID®, a novel intradermal injection device
por: Beyers, Koen C.L., et al.
Publicado: (2023)

CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer
por: Wettstein, Marian S., et al.
Publicado: (2015)

Regulation of motility in nonmuscle cells
Publicado: (1977)

Erectile dysfunction in nonmuscle-invasive bladder cancer patients before and after transurethral resection (TUR) of bladder tumor in China
por: Guo, Peng, et al.
Publicado: (2021)

Model of the VAX-11/780
Publicado: (1977)

Cannot write session to /tmp/vufind_sessions/sess_nd8au96uvokirla9tvi9rdg5d3